New biotech stock Kardigan may reveal Wall Street’s next move ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

The drug and biotech sector is in a recovery mode, after going through a difficult period between 2022 and 2024, backed by ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

Bio-Techne Is a Top S&P 500 Stock Today. Germany’s Merck Is Paying a 24% Premium for the Company. Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.